Background At the end of 2018, South Africa updated its all-oral regimen, to include
bedaquiline (BDQ) and 2 months of linezolid (LZD) for all patients initiating the shorter 9–12 …

Isoniazid-resistant tuberculosis: A problem we can no longer ignore | PLOS Medicine Skip to
main content Advertisement PLOS Medicine Browse Current Issue Journal Archive Special …

Tuberculosis (TB) is still a major health problem worldwide. Especially, multidrug-resistant
TB (MDR-TB), which is defined as TB that shows resistance to both isoniazid and rifampicin …

Background Drug resistance threatens global tuberculosis control. We aimed to examine
mortality in patients with tuberculosis from high-burden countries, according to concordance …

The antibiotic pyrazinamide (PZA) is a cornerstone of tuberculosis (TB) therapy that shortens
treatment durations by several months despite being only weakly bactericidal. Intriguingly …

Background Clofazimine is in widespread use as a key component of drug-resistant TB
regimens, but the recommended dose is not evidence based. Pharmacokinetic data from …

Developing new effective treatment strategies to overcome the rise in multi-drug resistant
tuberculosis cases (MDR-TB) represents a global challenge. A host-directed therapy (HDT) …

Tuberculosis (TB) remains the leading cause of death by an infectious pathogen worldwide,
and drug-resistant TB is a critical and rising obstacle to global control efforts. Most scientific …

Abstract The US Food and Drug Administration approved a 6-month regimen of pretomanid,
bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis …

Introduction An estimated 30,000 children develop multidrug-resistant (MDR) tuberculosis
(TB) each year, with only a small proportion diagnosed and treated. This field has historically …